Our infectious disease antigen portfolio currently features a comprehensive panel of recombinant HIV antigens developed to support the next generation of serological and fourth-generation diagnostic assays. Covering clinically important HIV-1 and HIV-2 targets, including gp120, gp41 (Subtype B and Group O), gp36, and p24 (Subtype C), the portfolio is engineered to provide broad diagnostic coverage, regional relevance, and exceptional analytical performance.
As part of Fluorobiotech's expanding immunodiagnostics portfolio, additional recombinant antigens targeting other high-impact infectious diseases will be introduced, providing researchers and diagnostic manufacturers with an increasingly comprehensive source of high-quality reagents for assay development and commercial diagnostic applications.
Our recombinant antigens are engineered to support excellent sensitivity, specificity, and reproducibility across multiple immunodiagnostic platforms.
All antigen products are manufactured under our ISO 13485-certified quality management system to ensure consistent quality and traceability.
Fluorobiotech provides scalable recombinant antigen production capabilities to support both development-stage and commercial diagnostic programs.
Optimized recombinant manufacturing workflows enable dependable long-term supply and reproducible antigen performance.
Our proprietary SelfPrep technology and efficient production systems enable more affordable access to high-quality diagnostic antigens.
Hammanshand Road,
Stellenbosch Central,
7599
info@fluorobiotech.com
+27 87 265 4363
Address
Phone
CONTACT FORM